Alchemia Ltd. is a biopharmaceutical company with a balanced portfolio of assets: 1) An established revenue stream from fondaparinux sodium sold by Dr. Reddy's Laboratories Ltd., 2) A late-stage oncology pipeline, including HA-Irinotecan, nearing completion of Phase 3 in metastatic colorectal cancer and 3) a drug discovery platform used to access 3-D chemical diversity.